NCT04879849
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have at least 2 measurable lesions, one inside and one outside the radiation field – the tumor outside the radiation field must be accessible for biopsy
Exclusions: Patients who have not progressed on checkpoint inhibitors (e.g. Keytruda, Tecentriq) in a prior line of therapy; Patients with unstable brain metastases that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT04879849